Guo Xinyi, Chitale Poonam, Sanjana Neville E
New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.
Department of Biology, New York University, New York, NY, 10003, USA.
Adv Exp Med Biol. 2017;1016:123-145. doi: 10.1007/978-3-319-63904-8_7.
Over the past few years, programmable RNA-guided nucleases such as the CRISPR/Cas9 system have ushered in a new era of precision genome editing in diverse model systems and in human cells. Functional screens using large libraries of RNA guides can interrogate a large hypothesis space to pinpoint particular genes and genetic elements involved in fundamental biological processes and disease-relevant phenotypes. Here, we review recent high-throughput CRISPR screens (e.g. loss-of-function, gain-of-function, and targeting noncoding elements) and highlight their potential for uncovering novel therapeutic targets, such as those involved in cancer resistance to small molecular drugs and immunotherapies, tumor evolution, infectious disease, inborn genetic disorders, and other therapeutic challenges.
在过去几年中,诸如CRISPR/Cas9系统等可编程RNA引导核酸酶在多种模式系统和人类细胞中开创了精确基因组编辑的新时代。使用大型RNA引导文库进行的功能筛选可以探究庞大的假设空间,以确定参与基本生物学过程和疾病相关表型的特定基因和遗传元件。在此,我们综述了近期的高通量CRISPR筛选(例如功能丧失、功能获得和靶向非编码元件),并强调了它们在揭示新治疗靶点方面的潜力,这些靶点涉及癌症对小分子药物和免疫疗法的抗性、肿瘤进化、传染病与生俱来的遗传疾病以及其他治疗挑战。